A key step towards reducing the burden of central nervous system (CNS) disorders is the identification of disease-specific biomarkers that can help predict, monitor, and guide treatment development.

Guanosine, a purine nucleoside, has emerged as a potent modulator within the central nervous system (CNS), contributing to neuroprotection through a diverse array of mechanisms. It plays a critical ...

The central nervous system (CNS) critically depends on the integrity of oligodendrocytes, specialised glial cells responsible for the formation and maintenance of myelin sheaths. Myelin not only ...

Racism, discrimination, and social determinants of health have contributed to clear disparities in health and health outcomes, particularly in central nervous system (CNS) disorders. Recognizing the ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

This color-coded graphic shows different populations of cells in the mouse brain, each one targeted by one of the genetic tools developed by scientists at the Allen Institute and other institutions.

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Monday ...

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with ...

FILE - The Johnson & Johnson headquarters in New Brunswick, New Jersey, on Feb. 8, 2024. (AP Photo/Ted Shaffrey, File) (Ted Shaffrey, Copyright 2024 The Associated ...

Read full article: Houston Police are investigating a stabbing at a home on West Alabama Street. Read full article: See these Insider Deals for home, beauty and sports enthusiasts Hassle-free PDFs are ...